What is the recommended initial dose of an ACE inhibitor (angiotensin‑converting enzyme inhibitor) or an ARB (angiotensin receptor blocker) for a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Initial Dosing of ACE Inhibitors and ARBs

Start with the lowest recommended initial dose from the table below, then uptitrate to target doses over weeks to months as tolerated.

Starting Doses by Agent

ACE Inhibitors 1, 2, 3:

  • Enalapril: Start 2.5 mg twice daily → Target 10-20 mg twice daily
  • Lisinopril: Start 2.5-5 mg once daily → Target 20-40 mg once daily
  • Ramipril: Start 1.25-2.5 mg once daily → Target 10 mg once daily
  • Captopril: Start 6.25 mg three times daily → Target 50 mg three times daily
  • Fosinopril: Start 5-10 mg once daily → Target 40 mg once daily
  • Perindopril: Start 2 mg once daily → Target 8-16 mg once daily
  • Quinapril: Start 5 mg twice daily → Target 20 mg twice daily
  • Trandolapril: Start 1 mg once daily → Target 4 mg once daily

ARBs 1, 2, 3:

  • Losartan: Start 25-50 mg once daily → Target 50-150 mg once daily
  • Valsartan: Start 20-40 mg twice daily → Target 160 mg twice daily
  • Candesartan: Start 4-8 mg once daily → Target 32 mg once daily

Critical Uptitration Strategy

The target doses listed above are what proved effective in clinical trials for reducing mortality and morbidity 1, 2. These medications were studied by starting low and systematically increasing to target doses regardless of symptom improvement at lower doses. Even if patients feel better on lower doses, continue uptitrating to achieve the proven target doses unless side effects prevent this 2, 3.

Monitoring Schedule

Reassess within 1-2 weeks after initiation or dose changes 1, 4:

  • Blood pressure (including orthostatic measurements)
  • Serum creatinine
  • Serum potassium

When to Continue vs. Adjust

Continue uptitrating if 4:

  • Creatinine rises <30% from baseline
  • Potassium remains manageable with dietary modification or potassium binders
  • Blood pressure tolerates increase (not causing symptomatic hypotension)

Stop or reduce dose if 4:

  • Creatinine rises >30% within 4 weeks
  • Uncontrolled hyperkalemia despite medical management
  • Symptomatic hypotension
  • Angioedema (permanently discontinue all ACE inhibitors; use extreme caution with ARBs) 1, 5

Context-Specific Considerations

For Heart Failure with Reduced Ejection Fraction

Start at the low end of dosing ranges and uptitrate systematically to target doses over 2-3 months 1, 2, 3. The mortality benefit comes from achieving target doses, not just starting therapy.

For Hypertension

Can start with slightly higher initial doses in uncomplicated hypertension 6, 7, 8. For example, lisinopril 10 mg daily or losartan 50 mg daily are reasonable starting points in otherwise healthy hypertensive patients.

For Chronic Kidney Disease with Albuminuria

Titrate to the highest approved dose tolerated 4. These patients particularly benefit from maximal renin-angiotensin system blockade, but require closer monitoring of creatinine and potassium.

Common Pitfalls to Avoid

First-dose hypotension risk is highest in 9:

  • Volume-depleted patients
  • Those on multiple antihypertensives
  • Elderly patients
  • Heart failure patients
  • Renovascular hypertension

For high-risk patients, observe for at least 6 hours after the first dose 9.

Never combine ACE inhibitor + ARB - this increases adverse events without additional benefit 5, 10.

Absolute contraindications 1, 5:

  • Pregnancy (discontinue immediately if pregnant or planning pregnancy) 4
  • History of angioedema with ACE inhibitors (for ACE inhibitors)
  • Bilateral renal artery stenosis

The evidence consistently shows that starting low and going slow with systematic uptitration to proven target doses maximizes benefit while minimizing harm 2, 3, 11.

References

Research

Angiotensin converting enzyme inhibitors in the clinic: first-dose hypotension.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1987

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.